We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+26.76%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.78B
AUM Growth
+$199M
Cap. Flow
-$18.8M
Cap. Flow %
-1.06%
Top 10 Hldgs %
47.19%
Holding
82
New
6
Increased
3
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$38.6M
2
VERU icon
Veru
VERU
+$36.1M
3
EXEL icon
Exelixis
EXEL
+$24.2M
4
VTYX
Ventyx Biosciences
VTYX
+$18.8M
5
GOSS icon
Gossamer Bio
GOSS
+$13.8M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$37.1M
3
BPMC
Blueprint Medicines
BPMC
+$14.9M
4
BMEA icon
Biomea Fusion
BMEA
+$14.2M
5
NUVB icon
Nuvation Bio
NUVB
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.33%
2 Financials 0.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAWN
26
DELISTED
Day One Biopharmaceuticals
DAWN
$23.8M 1.34%
1,189,943
– –
NUVL
27
DELISTED
Nuvalent
NUVL
$23.5M 1.32%
1,210,192
– –
RCKT icon
28
Rocket Pharmaceuticals
RCKT
$340M
$23.4M 1.32%
1,466,051
– –
SRPT icon
29
Sarepta Therapeutics
SRPT
$1.57B
$22.1M 1.24%
200,000
– –
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.06B
$21.7M 1.22%
600,000
– –
ACAD icon
31
Acadia Pharmaceuticals
ACAD
$4.43B
$20.7M 1.16%
1,263,930
– –
EXEL icon
32
Exelixis
EXEL
$13.3B
$19.6M 1.1%
+1,250,000
New +$24.2M
PNT
33
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$19.3M 1.09%
2,500,000
– –
IOVA icon
34
Iovance Biotherapeutics
IOVA
$1.82B
$18.5M 1.04%
1,935,133
– –
RNAM
35
DELISTED
Avidity Biosciences
RNAM
$18.3M 1.03%
1,121,327
– –
KNTE
36
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$18.2M 1.02%
1,522,559
-325,000
-18% -$4.25M
PRTA icon
37
Prothena Corp
PRTA
$425M
$18.2M 1.02%
300,000
– –
BPMC
38
DELISTED
Blueprint Medicines
BPMC
$18.1M 1.02%
275,000
-232,374
-46% -$14.9M
NRIX icon
39
Nurix Therapeutics
NRIX
$2.41B
$16M 0.9%
1,224,892
– –
CGEM icon
40
Cullinan Oncology
CGEM
$1.01B
$13.8M 0.77%
1,074,082
– –
THRD
41
DELISTED
Third Harmonic Bio
THRD
$10.8M 0.61%
+570,417
New +$10.3M
ETNB
42
DELISTED
89bio
ETNB
$8.11M 0.46%
1,400,000
– –
FATE icon
43
Fate Therapeutics
FATE
$286M
$7.84M 0.44%
350,000
-150,000
-30% -$4.33M
ASND icon
44
Ascendis Pharma A/S
ASND
$16B
$7.23M 0.41%
70,000
– –
TSVT
45
DELISTED
2seventy bio
TSVT
$6.69M 0.38%
459,836
– –
NGM
46
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$6.54M 0.37%
500,000
– –
MIST icon
47
Milestone Pharmaceuticals
MIST
$138M
$6.42M 0.36%
698,861
-1,540,000
-69% -$11.7M
ALT icon
48
Altimmune
ALT
$552M
$6.38M 0.36%
+500,000
New +$7.38M
COGT icon
49
Cogent Biosciences
COGT
$6.65B
$6.34M 0.36%
425,000
– –
RAIN
50
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$5.73M 0.32%
1,175,000
– –
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Boxer Capital held 82 positions worth $1.78B, up 13% from $1.58B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Boxer Capital's Q3 2022 filing shows 6 new, 3 increased, 8 reduced and 9 closed positions. Its largest new stake was Veru: 250,000 shares worth $28.8M. The largest sale was Turning Point Therapeutics, Inc. Common Stock, an estimated $42.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q3 2022 buy was Veru: 250,000 shares worth $28.8M.
  • Boxer Capital added most to SpringWorks Therapeutics in Q3 2022, an estimated $38.6M increase.
  • Boxer Capital's biggest Q3 2022 reduction was Blueprint Medicines, cutting an estimated $14.9M.
  • Boxer Capital fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $42.9M.
  • Boxer Capital's ten largest holdings make up 47% of its $1.78B portfolio in Q3 2022.
  • Boxer Capital opened 6 new positions and closed 9 in Q3 2022.
  • Boxer Capital's portfolio value rose 13% quarter-over-quarter to $1.78B.

Based on Boxer Capital's 13F filing for Q3 2022, filed 14 Nov 2022.